Navigation Links
Cell Therapeutics, Inc. Announces Reverse Stock Split
Date:8/25/2008

Board of Directors approves 1-for-10 split ratio

SEATTLE, Aug. 25 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that its Board of Directors has authorized a 1-for-10 reverse split of its common stock. The reverse split will become effective as of August 31, 2008.

At the Cell Therapeutics Special Meeting in Lieu of Annual Meeting of Shareholders held on June 19, 2008, shareholders approved a proposal to authorize the Board, in its discretion, to effect a reverse split of CTI's outstanding common stock without further action by shareholders.

The primary purpose of the reverse split is to increase the per-share trading price of CTI's stock in order to regain compliance with the NASDAQ Marketplace Rules for continued listing on the NASDAQ Global Market and to potentially appeal to a broader range of investors.

The reverse split will affect all outstanding shares of CTI's common stock as well as the number of shares of common stock underlying stock options and other exercisable or convertible instruments outstanding at the effective time of the reverse split but will not affect the number of authorized shares.

Upon the effectiveness of the reverse stock split, CTI shareholders will receive one new share of CTI common stock in exchange for every ten shares they hold. CTI's common stock will begin trading on a split-adjusted basis on the MTA in Milan on September 1, 2008 and will begin trading on a split-adjusted basis on the NASDAQ Global Market on September 2, 2008 under the temporary trading symbol "CTICD" in order to inform the investment community of the reverse stock split (MTA trading symbol shall not change). The trading symbol will revert to "CTIC" on September 30, 2008.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release includes forward-looking statements about the potential benefits of the reverse stock split that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties include the possibility that our stock price may decline following the reverse split, the possibility that we may not be able to sustain a trading price adequate to maintain the listing standards for the NASDAQ Global Market even with the split, the possibility that we may not meet other criteria for continued listing on the NASDAQ Global Market in the future even if our stock price stays above the minimum bid price, as well as the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

F: 206.272.4434

E: media@ctiseattle.com

http://www.celltherapeutics.com/media.htm

Investors Contact:

Ed Bell

T: 206.282.7100

Lindsey Jesch

T: 206.272.4347

F: 206.272.4434

E: invest@ctiseattle.com

http://www.celltherapeutics.com/investors.htm


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
2. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
3. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
6. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
7. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
8. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
9. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
10. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
11. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016 On Thursday, February 11, ... for community, health and disaster services, and the ... to enhance care coordination and service delivery for the ... need and to better connect service providers to the ... San Diego has handled more than ...
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... -- - New FDA action date of July ... date of July 22, 2016   --> ... 2016   - Lifitegrast has the potential ... the treatment of signs and symptoms of dry eye disease in ... be the only product approved in the U.S. in the past decade indicated for the ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu ... quad LC-MS, host live demos and poster sessions, and present on the analysis ... conference takes place March 6 to 10 at the Georgia World Congress Center ...
Breaking Biology Technology:
(Date:2/1/2016)... Fla. , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ... and television personality, Joey Fatone . Las Vegas ... greet fans. --> Las Vegas , where ... --> The new video ad was filmed at the Consumer ... appeared at the Wocket booth to meet and greet fans. ...
(Date:1/27/2016)... 2016  Rite Track, Inc. a leading semiconductor equipment ... Chester, Ohio announced today the acquisition of PLUS ... in Austin, Texas , will significantly ... modifications, installations and technical support offerings for TEL Track ... commented, "PLUS has provided world class service including refurbishment, ...
(Date:1/25/2016)... , Jan. 25, 2016  Glencoe Software, the ... pharma and publication industries, will provide the data management ... Centre (NPSC). ... Phenotypic analysis measures ... whole organisms, allowing comparisons between states such as health ...
Breaking Biology News(10 mins):